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ABSTRACT 
 
Background: Heart failure [HF] is a major health burden globally and contributes significantly to 
morbidity and mortality related to cardiovascular disease. The aim was to determine the outcome 
and factors that determine these outcomes of patients admitted for acute HF and followed up for 
six months. 
Methodology: A hospital-based prospective study. Subjects consisted of consecutive patients with 
confirmed diagnosis of acute HF admitted into the medical wards of the University of Port Harcourt 
Teaching Hospital [UPTH] in Nigeria over 1 year. All had full physical examination and relevant 
investigations including echocardiography. Subjects were followed up for six months and 
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reassessed for outcome/endpoint which were rehospitalisation or death. Factors that predicted 
these outcomes were also determined. 
Results: There were 160 subjects, 84 females and 76 males, age range 20 to 87 years, mean 
52.49±13.89 years. Sixteen (16) subjects (10.0%) were lost to follow up, 66(41.3%) showed 
improvement clinically, 57(35.6%) were rehospitalised while 21(13.1%) died. Determinants of 
rehospitalisation were New York Heart Association (NYHA) class, heart failure type, haemoglobin 
level at presentation and the estimated glomerular filtration rate (e GFR). Determinants of mortality 
were NYHA class and left ventricular ejection fraction at presentation. 
Conclusion: Heart failure rehospitalisation and mortality rates of 35.6% and 13.1% respectively is 
high compared to developed countries.  
 
 
Keywords: Heart failure; outcomes; rehospitalisation; mortality. 
 
1. INTRODUCTION 
 
Heart failure (HF) is the end stage of most 
diseases of the heart and is a major cause of 
morbidity and mortality. Thomas Lewis aptly 
captured the high premium placed on HF as far 
back as 1933 when he remarked, “The very 
essence of cardiovascular practice is the early 
detection of heart failure”. [1] The worldwide 
prevalence and incidence rates of HF are 
approaching epidemic level, as evidenced by the 
increase in the number of HF hospitalizations, 
the increasing number of HF-attributable 
mortalities and morbidity [2,3]. Worldwide, HF 
affects almost 23 million people [2] and up to 
three million people in the United Kingdom are 
affected [4]. The financial burden of HF in most 
countries is very substantial. In the United States 
about $30.7 billion was spent directly or indirectly 
on HF management in 2012 and projected to rise 
to 69.7 billion dollars by 2030 [5]. The peak 
incidence of HF in African patients remains in the 
fifth decade [6] and the hospital case fatality 
ranges from 9% to 12.5% [7]. This high death 
rate ranks HF among the major causes of death 
of cardiovascular origin in Africa [7]. In Port 
Harcourt, Niger Delta region of Nigeria, HF                   
was the third commonest non communicable 
cause of admission (next to diabetes and its 
complications and cerebrovascular disease) and 
contributed 9.6% of patients admitted to the 
medical wards over a 5 year period [8-9]. The 
prognosis of HF is uniformly poor as five                    
year mortality remains high at 50% and factors 
such as late presentation in advance heart 
failure, low haemoglobin level and impaired renal 
function have been identified as contributory 
factors for this poor outcome [10-16]. The aim of 
the study was to determine the short                        
term [6 months] outcome and factors that 
influence these outcomes in patients admitted 
with acute heart failure in Port Harcourt, 
Southern Nigeria. 
2. METHODOLOGY 
 
The was a hospital-based prospective study 
carried out in the medical wards of the University 
of Port Harcourt Teaching Hospital (UPTH), Port 
Harcourt, Niger Delta region of Nigeria. All the 
patients admitted into the medical wards with a 
confirmed diagnosis of acute heart failure [AHF] 
from 1st January to 31st December 2014 for the 
first time were recruited. The patients were 
selected if they met the Framingham [17] clinical 
criteria for the diagnosis of HF and confirmed           
on echocardiography. Demographic data was 
obtained from all patients aged 18-years and 
above who gave written informed consent. The 
hospital’s ethics committee approved the study. 
The NYHA functional class, baseline clinical and 
demographic characteristics of patients were 
obtained using a structured questionnaire.            
All study subjects underwent full clinical 
examination, anthropometric measurements            
and relevant investigations including                
chest radiographs, electrocardiograms, and 
echocardiogram. In addition the list of drugs 
prescribed on admission was also obtained for all 
participants.  
 
Blood pressure was measured with a standard 
mercury sphygmomanometer (cuff size 12.5 X 40 
cm) on the patient using standard protocol. 
Systolic and diastolic blood pressures were taken 
at korotkoff phases 1 and 5 respectively to the 
nearest 2 mmHg [18]. An average of two 
measurements taken 5 minutes apart were 
recorded and hypertension was deemed present 
if systolic BP ≥ 140 mmHg and or diastolic BP ≥ 
90 mmHg on at least 2 occasions or if patient 
was receiving anti-hypertensive drug treatment. 
[18]. 
 
Waist circumference was measured in 
centimeters at the midpoint between the lower 
costal margin and the iliac crest with the patient 
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standing and feet positioned close together and 
the value was read at the end of a normal 
expiration [19]. Waist circumference was 
considered increased when it exceeded 88 cm in 
women and 102 cm in men [19]. Hip 
circumference was measured in centimeters by 
the same method as for waist circumference but 
at the level of the greater trochanter. Waist-hip 
ratio was calculated by dividing the waist 
circumference by the hip circumference [19]. 
Weight was measured with a mechanical 
weighing scale with the subject wearing only light 
clothing, and height was measured using a 
stadiometer with the subject standing feet 
together without shoes or head gear, and reading 
taken to the nearest 0.5 cm. Body mass index 
was calculated using the formula Wt[Kg]/Ht[M]2. 
Body mass index status was classified according 
to the WHO criteria as normal weight (18.5-24.9 
kg/m2), overweight (25–29.9 kg/m2), class I 
obesity (30.0-34.9 kg/m2), class II obesity (BMI 
35.0-39.9 kg/m2), and morbid obesity (BMI ≥ 40 
kg/m2) [19].  
 
Blood samples were collected from all patients 
and analyzed for haemoglobin, fasting lipid 
profile, serum urea and creatinine as well as 
plasma glucose. Serum creatinine was used to 
calculate the eGFR using the Cockcroft-Gault 
formula [20]. Severity of renal impairment was 
classified using the National Kidney Foundation-
developed criteria as part of its Kidney Disease 
Outcomes Quality Initiative (NKF KDOQI) to 
stratify chronic kidney injury [21]. Fasting        
serum cholesterol and triglyceride levels were 
measured using the enzymatic method with a 
reagent from Atlas Medical Laboratories. Fasting 
HDL was measured with the precipitation 
method. LDL cholesterol values were calculated 
using the Friedwald equation when the 
triglyceride level was less than 4.0mmol/l: LDL = 
TC – (HDL + TG /2.2) [22].  
 
Standard 12 lead elctrocardiography was 
performed for all patients and the parameters 
assessed in the electrocardiogram included 
presence of atrial fibrillation, pathological                     
Q waves, left ventricular hypertrophy, QT 
prolongation and ST abnormalities. The 
abnormalities on the ECG was deemed to be 
confirmed if both authors independently agreed 
to it. Transthoracic echocardiography was 
performed on all the subjects and assessments 
were done according to the recommendations of 
the American Society of Echocardiography [23]. 
Left Ventricular systolic performance was 
assessed using the fractional shortening (FS) 
and the ejection fraction (EF) of the left ventricle. 
These were calculated automatically by the 
machine using the Teichoiz formula [24]. The left 
ventricular mass (LVM) was calculated using             
the American society of Echocardiography 
recommended formula for estimation of LV mass 
from LV linear dimensions [25]. Left Ventricular 
mass index (LVMI) was calculated by indexing 
the left ventricular mass to the body surface 
area. Left ventricular hypertrophy (LVH) was 
defined in absolute terms as LVMI >115 g/m2 in 
men and >95 g/m2 in women [25]. Left ventricular 
diastolic function was evaluated by studying the 
filling dynamics of the left ventricle, the 
isovolumetric relaxation time (IVRT), the 
pulmonary venous flow and tissue Doppler 
imaging derived myocardial wall velocities [26].    
 
2.1 Follow-up    
 
All the study population patients were followed 
up for 6 months or until death if the patient died 
before 6 months of follow up. They were 
assessed during follow up by telephone contacts 
if they did not keep outpatient appointment. The 
contact was either patient or next of kin phone 
contacts and were considered lost contact if 
telephone contact could not be made after three 
months of several calls or stated address was 
not within the city and not traceable in the village 
documented as residence. The primary end    
point was death due to any cause and 
rehospitalization. The duration of follow-up was 
defined as the interval from the date of the index 
examination at which the echocardiogram was 
obtained to the date of death or the date of last 
contact. During six months follow up, clinical and 
echocardiographic parameters were obtained 
and compared with initial values. All the subjects 
who required readmission had worsening of 
symptoms and a repeat echocardiographic 
assessment in all, showed low LV ejection 
fraction 
 
2.2 Statistical Analysis 
 
Data was analyzed using Statistical Package for 
Social Sciences (SPSS) version 20.0 Results 
were presented as mean ± standard deviation for 
continuous variables while categorical variables 
were expressed as proportions or percentages. 
Charts and tables were used to illustrate results 
where appropriate. Continuous variables were 
compared by the student’s t- test, while 
proportions or categorical parameters were 
compared with the chi-square test or two tailed 
Fisher’s exact test. Multiple logistic regression 
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analysis was done to test associations and a              
p value of less than 0.05 was considered 
statistically significant.  
 
3. RESULTS 
 
A total of 160 patients were studied over the 
study period and were made up of 84 females 
and 76 males. The age range was 20 to 87 years 
with a mean of 52.49±13.89 years. A total of 16 
subjects (10%) were lost to follow up, 66 subjects 
(41.3%) improved clinically and continued their 
regular out-patient clinic attendance for six 
months, 57 subjects (35.6%) were re hospitalised 
for worsening of HF symptoms while 21             
subjects (13.1%) died. The socio demographic 
profile of the patients did not have any significant 
effect on re hospitalisation and mortality. There 
was significant association between re 
hospitalisation and NYHA class, type of HF 
(systolic or diastolic heart failure), body                    
mass index (BMI), haemoglobin level, left 
ventricular ejection fraction (LVEF) and the 
eGFR. (Table 1). However when the effects of 
confounding variables were removed using                    
the logistic regression model, the real 
determinants of re hospitalisation were the NYHA 
class, the type of heart failure, the haemoglobin 
level and the eGFR. (Table 2). There was 
significant association between mortality and 
NYHA class, haemoglobin level and LVEF     
(Table 3). However after logistic regression 
analysis only the NYHA class and the                      
left ventricular ejection fraction at presentation 
were the real determinants of mortality            
(Table 4). 
                                                         
Table 1. Association of different variables with rehospitalisation 
 
Variable Rehospitalisation 
No. no (%) Yes. no (%) Total no Chi (p) 
Sex 
Male 
Female 
 
52 (68.4) 
51 (60.7) 
 
24 (31.6) 
33 (39.3) 
 
76 
84 
1.033 (0.309) 
Age group (years) 
18-45 
45-65 
>65 
 
26 (52.0) 
56 (70.9) 
21 (67.7) 
 
24 (48.0) 
23 (29.1) 
10 (32.3) 
 
50 
79 
31 
4.95 (0.084) 
LOE 
None and Primary 
Secondary/Tertiary  
 
29 (67.4) 
74 (63.2) 
 
14 (32.6) 
43 (36.8) 
 
43 
117 
0.24 (0.623) 
NYHA class at presentation 
Class 2 
Class3 
Class 4 
 
39 (90.7) 
44 (47.8) 
20 (80.0) 
 
4 (9.3) 
48 (52.2) 
5 (20.0) 
 
43 
92 
25 
26.64 (<0.001) 
Type of HF 
DHF 
SHF 
 
14 (93.3) 
89 (61.4) 
 
1 (6.7) 
56 (38.6) 
 
15 
145 
6.05 (0.014) 
BMI (Kg/m2) 
≤24.99 
25-29.99 
≥30 
 
34 (64.2) 
35 (52.2) 
34 (85.0) 
 
19 (35.8) 
32 (47.8) 
6 (15.0) 
 
53 
67 
40 
11.72 (0.003) 
Haemoglobin (gm) 
≥10 
<10 
 
84 (69.4) 
19 (48.7) 
 
37 (30.6) 
20 (51.3) 
 
121 
39 
5.51 (0.019) 
LVEF (%) 
≥40 
25-39.99 
<25 
 
48 (77.4) 
40 (56.3) 
15 (55.6) 
 
14 (22.6) 
31 (43.7) 
12 (44.4) 
 
62 
71 
27 
7.52 (0.023) 
cGFR (mls/min) 
≥60 
<60 
 
76 (73.8) 
27 (47.4) 
 
27 (26.2) 
30 (52.6) 
 
103 
57 
11.17 (0.001) 
Key: LOE=Level of education; NYHA= New York Heart Association; DHF= diastolic heart failure; SHF= systolic 
heart failure; BMI= body mass index; LVEF= Left ventricular ejection fraction; eGFR= estimated glomerular 
filteration rate; No= number; %= percent within variable; * = significant p value 
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Table 2. Result of logistic regression analysis of some variables with rehospitalisation 
 
 Sig. P value Odds ratio 
NYHA class 2 .000  
NYHA class 3 .271 2.778 
NYHA class 4 .000 16.763 
Type of HF .032 15.041 
BMI < 24.99 .410  
BMI 25- 29.9 .812 1.171 
BMI >>30.0 .285 1.886 
HB <10.0gm% .012 4.187 
EF>> 40.0% .475  
EF 25.0 – 39.99 .225 .415 
EF < 25.0% .435 .631 
eGFR< 60.0mls/min .024 2.960 
Key: NYHA= New York Heart Association; BMI= body mass index; LVEF= Left ventricular ejection fraction; 
cGFR= estimated glomerular filteration rate; * = significant p value 
 
Table 3. Association of some variables with mortality 
 
Variables Mortality Total no Chi (p value) 
No no (%)         Yes no (%) 
Sex         
Male 
Female 
 
63 (82.9) 
76 (90.5) 
 
13(17.1) 
8(9.5) 
 
76 
84 
 
2.01 (0.156) 
Age group      
18-45 
 46-65 
 >65 
 
43 (86.0) 
72 (91.1) 
24 (77.4) 
 
7(14.0) 
7(89) 
7(22.6) 
 
50 
79 
31 
 
3.724 (0.155) 
LOE 
Nursary and primary 
Secondary and tertiary 
 
36 (95.3) 
103 (88.0) 
 
7 (16.3) 
14 (12.0) 
 
43 
117 
 
0.513 (0.474) 
NYHA class 
Class 2 
Class 3 
Class 4 
 
41 (95.3) 
88 (95.7) 
10 (40.0) 
 
2 (4.7) 
4 (4.3) 
15 (60.0) 
 
43 
92 
25 
 
57.10 (<0.001) 
Type of HF 
 DHF 
 SHF 
 
15 (100.0) 
124 (85.5) 
 
0 (0.0) 
21(14.5) 
 
15 
145 
 
2.501 (0.114) 
BMI (Kg|m2 ) 
≤24.99 
25-29.99 
 ≥30 
 
45 (84.9) 
55 (82.1) 
39 (97.5) 
 
8 (15.1) 
12 (17.9) 
1 (2.5) 
 
53 
67 
40 
 
5.49 (0.064) 
Haemoglobin(gm/dl) 
≥10 
<10 
 
110 (90.9) 
29 (74.4) 
 
11 (9.1) 
10 (25.6) 
 
121 
39 
 
7.09 (0.008) 
LVEF (%) 
≥40 
25-39.99 
 <25 
 
60 (96.8) 
57 (80.3) 
22 (81.5) 
 
2 (3.2) 
14 (19.7) 
5 (18.5) 
 
62 
71 
27 
 
8.72 (0.013) 
cGFR(mls/min) 
≥60 
<60 
 
93 (90.3) 
46 (80.7) 
 
10 (9.7) 
11(19.3) 
 
103 
57 
 
2.96 (0.085) 
Key: LOE=Level of education;NYHA= New York Heart Association; DHF= diastolic heart failure; SHF= systolic 
heart failure; BMI= body mass index; LVEF= Left ventricular ejection fraction; eGFR= estimated glomerular 
filteration rate; No= number; %= percent within variable 
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The treatment chart showed that most 
participants received standard treatment for heart 
failure as all patients received a loop diuretic on 
admission, 98% received either an angiotensin 
receptor blocker or angiotensin converting 
enzyme inhibitor. 80% of all participants received 
a mineralocortiocid receptor antagonist, 75% 
received low dose aspirin, 11% received warfarin 
95% received digoxin. None received a beta 
blocker on admission but 77% were prescribed a 
beta blocker on discharge. Thus more than 80% 
of all participants received standard guideline 
recommended treatment for heart failure and the 
trend is not surprising the center being a tertiary 
health institution and a post graduate medical 
training center Table 5. 
 
Table 4. Logistic regression analysis of some 
variables with mortality 
 
 P value Odds ratio 
 NYHA class 2 .000  
 NYHA class 3 .001 1.90 
NYHA class 4 .000 9.00 
HB < 10.0 gm% .950 1.049 
EF> 40% .018  
EF 25- 39.99% .643 1.798 
EF < 25.0% .014 14.621 
NYHA= New York Heart Association; LVEF= Left 
ventricular ejection fraction 
 
Table 5. Pattern of heart failure treatment 
 
Drug % age of patients 
Angiotensin converting 
Enzyme inhibitors/ 
Angiotensin Receptor 
Blocker 
98% 
Beta blockers NIL 
Loop diuretic 100% 
Mineralocorticoid 
Receptor antagonist 
80% 
Digoxin 95 
Warfarin 11% 
Low dose aspirin 75% 
 
4. DISCUSSION 
 
The study showed that in this cohort of patients 
from southern Nigeria, the average age of the 
patients with HF was 52.49±13.89 years, thus HF 
affects the most productive age or people in their 
prime. Reduced life expectancy, poor health 
infrastructure and an almost epidemic explosion 
of cardiovascular risk factors in Sub Saharan 
Africa and other low income countries are 
contributory factors. The lower average age in 
our study and that of other studies emanating 
from Africa has been attributed to the fact that 
the major causes of HF in sub-Saharan Africa 
such as hypertension, rheumatic heart disease, 
idiopathic dilated cardiomyopathy and HIV 
related heart disease which affects mainly the 
young and the middle-aged. Also hypertension 
detection, treatment and control in Nigeria as in 
other African countries is generally poor, hence 
heart failure and other complications are 
expected to occur earlier. This finding is at 
variance with those of patients in developed 
countries where HF remains predominantly a 
disease of the elderly [27-28]. In Spain, 
Permanyer et al. [29] found that almost 40% of 
HF patients were over 80 years, and more than 
70% were over 70 years of age. This is also 
similar to the pattern in other developed 
countries such as the United States of America 
where average age of HF patients was about 70 
years [30].  
 
The major etiology of heart failure detected          
in this study were hypertension, dilated 
cardiomyopathy and rheumatic valve disease 
accounting for 83.75% of all cases. Hypertension 
and hypertensive heart disease account for 
51.25% and is the most frequent etiology and is 
in keeping with studies from other parts of Africa 
[31-32]. This may account for the non use of beta 
blockers in the participants during admission 
whereas beta blockers are a major class of drug 
used in developed countries where heart failure 
is majorly due to ischemic heart disease. Late 
presentation of participants to the hospital was a 
significant finding in this study, with 57.5% of the 
participants presenting in NYHA class III and 
15.6% in class IV. This late presentation appears 
to be a common finding in African patients as 
studies from other investigators in the African 
continent show similar trend [15,33]. This late 
presentation at an advanced NYHA class has 
been shown to impacts negatively on the 
prognosis and outcome of heart failure 
participants [15]. This fact was also shown in this 
study where the severity of the NYHA functional 
class of the participants at presentation was 
found to be an important determinant of 
outcome. The late presentation of participants in 
this study may be attributable to lack of universal 
health insurance in our country as all the 
participants were paying out of pocket as at the 
time of the study.   
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4.1 Clinical Endpoints after 6 Months of 
Follow Up 
 
In this study, 10% of the patients were lost to 
follow-up and all attempts at location by 
telephone contact or physical address was futile 
and the reasons were not quite clear. The 
address of some of the participants were 
nonspecific and in rural areas, out of the city 
where our hospital is located. 
 
4.1.1 Rehospitalisation  
 
The rehospitalisation rate of HF in this study was 
35.6% and is quite high and unexpected as most 
of the patients received standard therapy for 
heart failure. The reason for this is not clear but 
several factors such as out of pocket drug 
purchases which make post discharge drug 
compliance difficult to ascertain. Also it is 
expected that the younger age of this cohort 
which means fewer co morbidities would have 
impacted positively on re hospitalisation but this 
was not so. Low quality drugs in circulation in the 
country may be an important cause of treatment 
failure which may contribute to the increased re 
hospitalisation rate. The determinants of re 
hospitalization in this study were the NYHA class 
at presentation, the higher NYHA [NYHA 3 AND 
4] being associated with higher readmission rate, 
the type of heart failure (systolic heart failure), 
low haemoglobin level (<10 gm/l) and low            
eGFR (eGFR values <60 mls/min). This re 
hospitalisation rate is higher than figures from the 
United States where Ross et al. [34], using the 
data from Medicare, documented 30-day 
readmission rates after HF hospitalization of 
23.0% in 2004, 23.3% in 2005, and 22.9% in 
2006. Ogah et al. [35] in a recent study in the 
south west region of Nigeria reported a 
rehospitalisation rate of 12.2% and identified 
presence of mitral regurgitation, age ≥ 60 years, 
presence of tricuspid regurgitation, atrial 
fibrillation and Left Ventricular Ejection      
Fraction as factors associated with 6months 
rehospitalization. Thus hospitalization and high 
rehospitalisation rate of HF patients pose 
substantial burden and continues to be of great 
public heath significance especially in a 
developing economy like Nigeria. 
 
4.1.2 Mortality  
 
The six months [180 days] mortality in this 
patient cohort was 13.1% and is considered high. 
The contributory factors may include well known 
negative predictive factors in heart failure such 
as late presentation in advanced heart failure, 
low ejection fraction, co morbidity such as 
anaemia and raised serum creatinine. Heart 
failure is a progressive disease that is ultimately 
fatal and the presence of several co morbidities 
would impact negatively on outcomes and raise 
the mortality. The 6monhs mortality in this cohort 
is similar to the figures documented for 
hypertensive HF patients in the same institution 
about two decades ago where investigators 
reported mortality rate of 13.6% [36]. This finding 
thus suggests that mortality from HF in our 
environment has remained relatively stable 
despite advances in treatment modalities. This 
mortality rate is also comparable to the mortality 
of 10% reported in the northern part of Nigeria 
though these were not longitudinal studies [37]. It 
was however much lower than the 30.8% 
documented from South Western part of Nigeria 
[33] and the 35% documented in Lusaka, Zambia 
[38]. The high mortality rate from Western 
Nigeria may however be attributable to the late 
presentation with more than 90% of them 
presenting in NYHA class IV while the Zambian 
investigators admitted logistic and financial 
challenges that made it difficult to optimize 
patient’s treatment. However Ogah et al. [35] in a 
recent study in the south west region of Nigeria 
reported a rehospitalization rate of 12.2% and 
mortality rate of 4.2% at 6 months of follow-up. In 
our cohort the identified determinants or 
predictors of 6months mortality were high NYHA 
class (Class III and IV) and low left ventricular 
ejection fraction (LVEF < 25%). Karaye et al. [37] 
in Northern Nigeria also noted the poor 
prognostic value of low LVEF of < 40%.  Age and 
anaemia did not appear to be significant in 
determining mortality outcome. This finding 
appear to be at variance with the result of other 
studies done within and outside Africa. Falase       
et al. [39] reported the prognostic importance                 
of anaemia in HF patients while Familoni et al. 
[15] also from Nigeria reported factors associated 
with poor outcome in HF patients to include 
anaemia, low eGFR, increased age and low 
haemoglobin of <10gm/dl. Nohria et al.                        
[3] documented high NYHA class, low                      
LVEF, advanced age, low eGFR, anaemia and 
other co-morbid conditions as factors that 
negatively affect outcome in HF patients. Using 
data from the sub-Saharan Africa Survey of 
Heart Failure (THESUS-HF), Sliwa et al. [40] 
also noted that the main predictors of 60-day re-
admission or death were a history of malignancy 
and severe lung disease, admission systolic 
blood pressure, heart rate and signs of 
congestion (rales), kidney dysfunction (BUN), 
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anaemia, HIV positivity and echocardiographic 
ejection fraction.  
 
Thus the determinants of mortality and 
rehospitalisation in this cohort of Nigerians is 
similar to findings from other parts of Nigeria and 
Sub Saharan Africa though some minor 
differences existed probably related to difference 
in sample size and availability of facilities for 
monitoring. This is not surprising since the 
etiology of heart failure in this region is similar 
and due mainly to hypertension, cardiomyopathy 
and rheumatic valvular heart disease. 
 
5. CONCLUSION 
 
As in other studies of HF patients in sub-Saharan 
Africa, heart failure patients in Port Harcourt, 
South South region of Nigeria are relatively 
young, being in their fifth to sixth decades of life 
and present in advanced NYHA functional state. 
The determinants of mortality were advanced 
NYHA class and low left ventricular ejection 
fraction while the determinants of re 
hospitalisation were advanced NYHA class, 
anemia, systolic heart failure and impaired renal 
function [low eGFR]. 
 
6. LIMITATION OF STUDY  
 
Small sample size and high attrition rate may not 
reflect the true relationship between variables 
and rehospitalisation as well as mortality.  
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